Immutep Ltd.'s partner CYTLIMIC recently presented the results of its YNP001 study at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting.
The YNP001 study is a First-in-Human study of the cancer peptide vaccine CYT001, a combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol, for patients (total 17) with advanced or metastatic solid cancer.
The poster concludes:
The combination cancer vaccine therapy using multi-HLA-restricted peptides and hLAG-3Ig + Poly-ICLC was safe and effective for treating the last line patients with metastatic solid tumors. The proportion of the PD-1+/CD4+ T cells and Treg Fraction II were the significant biomarker for OS.
#SITC18
https://www.cytlimic.com/news/20181012_en.html
Immutep Ltd.'s partner CYTLIMIC recently presented the results...
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.010(3.03%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.0¢ | 31.0¢ | $66.60K | 210.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 125475 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 8733 | 3 |
View Market Depth
| Last trade - 10.05am 26/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
